Sinew Pharma Inc.
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also… Read more
Sinew Pharma Inc. (6634) - Total Liabilities
Latest total liabilities as of June 2025: NT$35.10 Million TWD
Based on the latest financial reports, Sinew Pharma Inc. (6634) has total liabilities worth NT$35.10 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sinew Pharma Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Sinew Pharma Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sinew Pharma Inc. Competitors by Total Liabilities
The table below lists competitors of Sinew Pharma Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Altinyag Kombinalari AS
IS:ALMAD
|
Turkey | TL78.79 Million |
|
Khon Kaen Sugar Industry PCL
BK:KSL
|
Thailand | ฿23.49 Billion |
|
Afya Limited
SA:A2FY34
|
Brazil | R$4.44 Billion |
|
ICD Co. Ltd
KQ:040910
|
Korea | ₩60.99 Billion |
|
Horizon Space Acquisition II Corp. Units
NASDAQ:HSPTU
|
USA | $558.75K |
Liability Composition Analysis (2019–2024)
This chart breaks down Sinew Pharma Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 53.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinew Pharma Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinew Pharma Inc. (2019–2024)
The table below shows the annual total liabilities of Sinew Pharma Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$28.88 Million | -27.28% |
| 2023-12-31 | NT$39.71 Million | +38.58% |
| 2022-12-31 | NT$28.66 Million | +79.57% |
| 2021-12-31 | NT$15.96 Million | -8.26% |
| 2020-12-31 | NT$17.40 Million | -93.10% |
| 2019-12-31 | NT$252.01 Million | -- |